1. A Regulatory Authority’s Opinion About Surrogate Endpoints, Robert J. Temple, Food and Drug Administration

2. Special Article: Commentary Concerning Domonstratin of Safety and Efficacy of Investigational Anticancer Agents in Clinical Trials, Journal of Clinical Oncology, Vol 9, No 12 (December), 1991 : pp 2225-2232